Refractory Neurofibromatosis Type 1 clinical trials at UC Health
1 research study open to new patients
open to eligible people ages 3-21
This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.